Hypertrophic Scars - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：45頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hypertrophic Scars - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hypertrophic Scars - Pipeline Review, H1 2014’, provides an overview of the Hypertrophic Scars’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypertrophic Scars, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertrophic Scars and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypertrophic Scars
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypertrophic Scars and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypertrophic Scars products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypertrophic Scars pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypertrophic Scars
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypertrophic Scars pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hypertrophic Scars - Pipeline Review, H1 2014’, provides an overview of the Hypertrophic Scars’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypertrophic Scars, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertrophic Scars and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypertrophic Scars
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypertrophic Scars and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypertrophic Scars products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypertrophic Scars pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypertrophic Scars
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypertrophic Scars pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypertrophic Scars Overview 6
Therapeutics Development 7
Pipeline Products for Hypertrophic Scars - Overview 7
Pipeline Products for Hypertrophic Scars - Comparative Analysis 8
Hypertrophic Scars - Therapeutics under Development by Companies 9
Hypertrophic Scars - Therapeutics under Investigation by Universities/Institutes 10
Hypertrophic Scars - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypertrophic Scars - Products under Development by Companies 13
Hypertrophic Scars - Products under Investigation by Universities/Institutes 14
Hypertrophic Scars - Companies Involved in Therapeutics Development 15
HanAll Biopharma Co., Ltd. 15
RXi Pharmaceuticals Corporation 16
vida therapeutics inc. 17
Hypertrophic Scars - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
RXI-109 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HL-156Fib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
V-2248 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Psoriasin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Koebnerisin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drug for Fibrotic Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Hypertrophic Scars - Recent Pipeline Updates 35
Hypertrophic Scars - Dormant Projects 39
Hypertrophic Scars - Discontinued Products 40
Hypertrophic Scars - Product Development Milestones 41
Featured News & Press Releases 41
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 41
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 41
Nov 13, 2013: RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45
List of Tables
Number of Products under Development for Hypertrophic Scars, H1 2014 7
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Hypertrophic Scars - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 15
Hypertrophic Scars - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 16
Hypertrophic Scars - Pipeline by vida therapeutics inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Hypertrophic Scars Therapeutics - Recent Pipeline Updates, H1 2014 35
Hypertrophic Scars - Dormant Projects, H1 2014 39
Hypertrophic Scars - Discontinued Products, H1 2014 40
List of Figures
Number of Products under Development for Hypertrophic Scars, H1 2014 7
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypertrophic Scars Overview 6
Therapeutics Development 7
Pipeline Products for Hypertrophic Scars - Overview 7
Pipeline Products for Hypertrophic Scars - Comparative Analysis 8
Hypertrophic Scars - Therapeutics under Development by Companies 9
Hypertrophic Scars - Therapeutics under Investigation by Universities/Institutes 10
Hypertrophic Scars - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypertrophic Scars - Products under Development by Companies 13
Hypertrophic Scars - Products under Investigation by Universities/Institutes 14
Hypertrophic Scars - Companies Involved in Therapeutics Development 15
HanAll Biopharma Co., Ltd. 15
RXi Pharmaceuticals Corporation 16
vida therapeutics inc. 17
Hypertrophic Scars - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
RXI-109 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HL-156Fib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
V-2248 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Psoriasin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Koebnerisin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drug for Fibrotic Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Hypertrophic Scars - Recent Pipeline Updates 35
Hypertrophic Scars - Dormant Projects 39
Hypertrophic Scars - Discontinued Products 40
Hypertrophic Scars - Product Development Milestones 41
Featured News & Press Releases 41
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 41
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 41
Nov 13, 2013: RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45
List of Tables
Number of Products under Development for Hypertrophic Scars, H1 2014 7
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Hypertrophic Scars - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 15
Hypertrophic Scars - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 16
Hypertrophic Scars - Pipeline by vida therapeutics inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Hypertrophic Scars Therapeutics - Recent Pipeline Updates, H1 2014 35
Hypertrophic Scars - Dormant Projects, H1 2014 39
Hypertrophic Scars - Discontinued Products, H1 2014 40
List of Figures
Number of Products under Development for Hypertrophic Scars, H1 2014 7
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
